Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Combination of Radiation Therapy and Irreversible Electroporation for Intermediate-Risk Prostate Cancer (RTIRE): A Phase 1 Trial.
Journal: Radiology
Published: July 28, 2026
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.
Journal: European urology oncology
Published: February 16, 2025
A Randomized Controlled Phase 2 Trial Comparing Salvage Radiotherapy for Prostate Cancer Delivered in 4 Versus 2 Weeks (SHORTER): Acute Genitourinary and Gastrointestinal Patient-reported Outcomes at a Single Institution.
Journal: European urology oncology
Published: February 16, 2025
Trends in Active Surveillance for Men With Intermediate-Risk Prostate Cancer.
Journal: JAMA network open
Published: August 22, 2024
Radiation therapy and IRreversible electroporation for intermediate risk prostate cancer (RTIRE).
Journal: BMC urology
Published: March 15, 2024
Differential Use of Radiotherapy Fractionation Regimens in Prostate Cancer.
Journal: JAMA network open
Published: October 10, 2023
A randomized phase II trial of MR-guided prostate stereotactic body radiotherapy administered in 5 or 2 fractions for localized prostate cancer (FORT).
Journal: BMC cancer
Published: June 09, 2023
Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning.
Journal: Journal for immunotherapy of cancer
Published: October 12, 2015
Harnessing the Microbiome to Enhance Cancer Immunotherapy.
Journal: Journal of immunology research
Published: April 08, 2015
Showing 1-9 of 9
Last Updated: 09/26/2026